<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05793502</url>
  </required_header>
  <id_info>
    <org_study_id>20230320</org_study_id>
    <nct_id>NCT05793502</nct_id>
  </id_info>
  <brief_title>Left Bundle Branch Pacing (LBBP) for the Treatment of Cardiac Dysfunction With Safety and Efficacy Study in Patients With Atrioventricular Block</brief_title>
  <official_title>Left Bundle Branch Pacing (LBBP) for the Treatment of Cardiac Dysfunction With Safety and Efficacy Study in Patients With Atrioventricular Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study periodically assessed patients' cardiac function and prognosis by cardiac&#xD;
      ultrasound, NYHA cardiac function class, 6-minute walk distance, quality of life score (QoL),&#xD;
      and clinical events at follow-up, with the aim of assessing whether LBBP is no less effective&#xD;
      than CRT in patients with left ventricular ejection fraction (LVEF) &lt;50% and estimated&#xD;
      percentage of ventricular pacing &gt;40% of cardiac dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2023</start_date>
  <completion_date type="Anticipated">March 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>12 months of LVEF</measure>
    <time_frame>12 months</time_frame>
    <description>LVEF at 12 months after implantation was analyzed to compare the LBBP treatment group with the CRT treatment group for the target subjects.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Consented to Participate in the Trial and Signed an Informed Consent Form</condition>
  <condition>NYHA Heart Function Classification of I-III</condition>
  <arm_group>
    <arm_group_label>LBBP</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>CRT</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LBBP/CRT</intervention_name>
    <description>The trial plans to enroll 160 patients with cardiac dysfunction who meet the enrollment criteria and agree to participate in the trial, and randomly assign them to the LBBP and CRT groups in a 1:1 ratio</description>
    <arm_group_label>CRT</arm_group_label>
    <arm_group_label>LBBP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cardiac dysfunction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be at least 18 years of age.&#xD;
&#xD;
          -  Consent to participate in the trial and have signed an informed consent form.&#xD;
&#xD;
          -  NYHA cardiac function classification of I-III.&#xD;
&#xD;
          -  LVEF &lt; 50%.&#xD;
&#xD;
          -  Ventricular pacing-dependent patients with second-degree or complete AV block with&#xD;
             pacing indications or ventricular pacing percentage &gt;40%.&#xD;
&#xD;
          -  Patients who are willing to implant a new implant or have their device replaced or&#xD;
             upgraded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;1 year.&#xD;
&#xD;
          -  Patients with severe tricuspid valve disease1 or who have undergone mechanical or&#xD;
             bioprosthetic valve surgery.&#xD;
&#xD;
          -  have had an acute myocardial infarction within 1 month&#xD;
&#xD;
          -  Women of childbearing potential who are pregnant or who become pregnant during the&#xD;
             study period.&#xD;
&#xD;
          -  Severe hepatic or renal dysfunction.&#xD;
&#xD;
          -  Have been enrolled in other clinical studies that may interfere with the objectives of&#xD;
             this trial.&#xD;
&#xD;
          -  Have evidence of severe pulmonary hypertension (PASP &gt; 70 mmHg).&#xD;
&#xD;
          -  Have evidence of hypertrophic cardiomyopathy that would affect the patient's&#xD;
             prognosis.&#xD;
&#xD;
          -  Subjects who, in the opinion of the investigator, are physically unfit to participate&#xD;
             in this trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chen Keping, Doctor</last_name>
    <phone>13811266140</phone>
    <phone_ext>+86</phone_ext>
    <email>chenkepingfw@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Jie, Bachelor</last_name>
    <phone>13811266140</phone>
    <phone_ext>+86</phone_ext>
    <email>lijie_mmtchina@163.com</email>
  </overall_contact_backup>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 20, 2023</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Chen Keping</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrioventricular Block</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a multicenter, prospective, randomized controlled trial. The trial plans to enroll 160 patients with cardiac dysfunction who meet the enrollment criteria and agree to participate in the trial, and randomly assign them to the LBBP and CRT groups in a 1:1 ratio. Patients who are successfully implanted will be enrolled for evaluation and follow-up.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

